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Abstract
Transketolase is an enzyme involved in a critical step of the non-oxidative branch of the pentose phosphate pathway whose
inhibition could lead to new anticancer drugs. Here, we report new human transketolase inhibitors, based on the phenyl
urea scaffold, found by applying structure-based virtual screening. These inhibitors are designed to cover a hot spot in the
dimerization interface of the homodimer of the enzyme, providing for the first time compounds with a suggested novel
binding mode not based on mimicking the thiamine pyrophosphate cofactor.
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Introduction
Transketolase (EC 2.2.1.1) is a homodimeric enzyme that
catalyses the reversible transfer of two carbons from a ketose donor
substrate to an aldose acceptor substrate. Transketolase is the most
active enzyme involved into the non-oxidative branch of the
pentose phosphate pathway [1], in charge of generating the ribose
molecules necessary for nucleic acid synthesis. Together with the
finding that this pathway is highly expressed in the cancer cell [2],
this enzyme provides an excellent target for novel chemothera-
peutic agents. Additionally, several crystal structures of this
enzyme are available [3,4,5,6,7] and notably, the human variant
of transketolase was recently reported as well [8] allowing the
rational structure-based design of human inhibitors.
The active centre of transketolase contains a thiamine
pyrophosphate cofactor, coordinated to a divalent metal ion,
whose binding site has been used for the development of enzyme
inhibitors. The most representative inhibitors that mimetize the
interactions of thiamine pyrophosphate are oxythiamine [9] and
thiamine thiazolone diphosphate [10]. Unfortunately, these
compounds lack selectivity as thiamine pyrophosphate is a
common cofactor found in multiple enzymes, such as pyruvate
dehydrogenase [11]. More recently, several thiamine antagonists
were designed with the aim of obtaining more selective inhibitors
with improved physical properties [12,13,14]. Nonetheless, it is
interesting to find additional binding sites allowing drug discovery,
not based on the active centre of transketolase but on critical
allosteric points of the enzyme. Here, we utilize the homology
model of human transketolase recently reported by our group [15]
to analyze the hot spot residues of the homodimeric interface and
perform a pharmacophore-based virtual screening. This strategy
yielded a novel family of compounds, containing the phenyl urea
group, as new transketolase inhibitors not based on antagonizing
thiamine pyrophosphate. The activity of these compounds,
confirmed in transketolase cell extract and in two cancer cell
lines, suggests that the phenyl urea scaffold could be used as novel
starting point to generate new promising chemotherapeutic agents
by targeting human transketolase.
Results and Discussion
Virtual screening protocol
The homology model of human transketolase [15] (see
Materials and Methods section) was used to analyze the most
stable contacts belonging to the dimer interface of the enzyme. It is
known that the active centre of transketolase containing thiamine
pyrophosphate is stabilized by contacts of the two subunits [8] and
thereby transketolase activity is closely related with its dimer
stability.
The dimer interface was evaluated through molecular dynamics
simulations [15] (see Materials and Methods section) calculating
the interaction energies between all residues of both monomers to
conclude that the conserved sequence D200-G210 fulfils the
criteria used for pharmacophore selection. The high sequence
conservation of D200-G210 with respect to the template (50%)
[15] was considered an important trend that could point to an area
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helix motif that interacts with the same fragment of the partner
monomer forming the antiparallel alpha helices structure shown in
Figure 1A. This sequence forms a hydrogen bond donor between
the amino group of Q203, of the first monomer, and the oxygen
atom of the carboxylate of E207, belonging to the second
monomer. Carboxylate of E207 of the first monomer forms two
hydrogen bond acceptors, with Q203 and K204 of the second
subunit. Finally, terminal amino of K204 of the first monomer
maintains a hydrogen bond donor with the carboxylate of E207, of
the second monomer. On the other hand, the analysis of van der
Waals energies revealed us that Q203 offers a major contribution
when interacting with the fragment D200-G210, providing around
28 kcal/mol and that residues K204 and E207 provided high
electrostatic energies (around 220 kcal/mol).
Accordingly, this alpha helix sequence was utilized to configure
a 5-point pharmacophore (Figure 1B) to perform a structure-based
virtual screening (see Materials and Methods section). This process
yielded 128 candidate molecules with a structure able to
accommodate the five interactions shown in the natural protein
sequence, and therefore with the potential ability to function as
dimerization inhibitors (Supplementary Material, Table S1). After
that, a docking procedure (see Materials and Methods section) was
carried out to refine the hit selection from the pool of candidates
applying a geometrical criterion (RMSd-based) and consensus
scoring employing the XSCORE function [16]. Best ranked
compounds were visually inspected and seven of them (named T1–
T7) were purchased for experimental validation.
In vitro enzymatic inhibition of transketolase and cell
viability inhibition
Most promising compounds were purchased as potential transke-
tolase inhibitors and tested for enzyme activity using spectrophoto-
metric and fluorimetric methods (see activity of two of them in
Supplementary Material Figure S1). Among the products tested for
transketolase activity, the compound showing the best inhibitory
action (T2, Figure 2) was selected to perform additional cell
proliferation assays (T1, T3, T5, T6 and T7 were inactive in the
enzymatic assay and T4 was too hydrophilic to penetrate into the cells,
so all of them were discarded). This compound presented an IC50 of
10 mMi nH T 2 9a n d9mM in HCT116 (see Materials and Methods
section) (Table 1). For comparison purposes, we also assessed the effect
of oxythiamine, a reference transketolase cofactor antagonist, resulting
in a much higher IC50 of 8 mM in both cell types.
Compound T2 derivatives and structure-activity analysis
Following the encouraging results of compound T2, a second
generation of diverse derivative molecules was purchased in order
to improve the inhibition activity. The docked structure of
compound T2 was considered here as a starting point to visualize
structural changes able to improve the interaction pattern.
The SciFinder (ACS) tool was used to search for commercially
available T2 derivatives and resulted in five most promising
compounds (T2A, T2B, T2C, T2D and T2E), whose binding
mode to transketolase was evaluated throughout docking and
scoring (see Materials and Methods section and Supplementary
Material Table S2). Additionally a compound not fulfilling the
pharmacophore was also purchased as a negative control
(compound T2F).
For the six compounds (Figure 2), an equivalent transketolase
inhibition test was performed, varying their concentration in the
range of 50 to 300 mM. The effect of these compounds over cell
proliferation was also studied in HT29 and HCT116 cell lines.
Results are summarized in Table 1. The thiourea derivative T2E
was poorly active confirming that the carbonyl group is essential
for transketolase inhibition. The negative control (compound T2F)
which lacks the fundamental nitro group showed no activity, as
expected seeming to confirm the suggested binding site. Com-
pound T2C which presents a carboxyl group as mimetic of the
nitro moiety was also inactive. Compound T2D showed no
inhibition of transketolase, suggesting that the meta ethyl groups in
the aromatic ring are probably too bulky or too hydrophobic for
maintaining a suitable binding. Conversely, compounds T2A and
specially T2B (Supplementary Material Figure S2), which are
more similar to the parent compound T2, showed a lower IC50
both in the transketolase inhibitory activity experiment and in the
cell viability assay (Table 1).
Both compounds can be considered as promising hits for
developing further human transketolase inhibitors.
Proposed binding mode and interaction energies of
compound T2 and its derivatives
Figure 3 shows the proposed binding mode of the compound T2
and its derivatives, and Table 2 lists the ligand-protein interaction
of the compounds extracted from the force field and also the
binding energies by applying an standard MMPBSA protocol (see
Materials and Methods) upon the minimized structures. In
compound T2 the nitro group interacts strongly with K204 by
forming a hydrogen bond, the two urea amino groups form two
Figure 1. Transketolase structure model. A) Homology model of human transketolase showing the antiparallel alpha helices involved in
dimerization. B) Close view of the alpha helix D200-G210 showing the selected residues of the 5-point pharmacophore. HY: hydrophobic contact, HA:
hydrogen acceptor, HD: hydrogen donor.
doi:10.1371/journal.pone.0032276.g001
New Transketolase Inhibitors
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32276hydrogen bonds with E207. Additionally, the hydroxyl group of
T2 also forms a third hydrogen bond with E207. Finally, the two
phenyl rings establish van der Waals contacts, mainly with the
hydrophobic part of side chains of Q203 and K204 (Figure 3). All
in all, the interactions of this compound with the alpha helix
sequence resemble remarkably the protein-protein recognition of
the two alpha helices in the homodimer of transketolase. Moreover
the proposed binding mode could explain the inactivity of
compounds T2F and T2C, since they lack the obligatory nitro
group. Table 2 shows that the electrostatics energies of the nitro
group are in between 222 and 225 kcal/mol; T2F binding lacks
this contribution and the carboxylate of T2C only offers
210 kcal/mol.
The bulky sulphur of the thiourea moiety of compound T2E
also affected negatively the binding affinity although the
MMPBSA interaction energies remained similar to the parent
compound T2 (Table 2). It is possible that the inactivity of T2E is
more related with a lower solubility of the compound. It is worth
mentioning that, except T2E, the MMPBSA energies are in
accordance with the experimental activities, being higher in the
active compounds (T2, T2A, T2B) as compared with the inactive
ones T2C, T2D and T2F.
Comparison with the crystal structure of human
transketolase
During the course of this research, the crystal structure of
human transketolase was made public (pdb code 3MOS) [8]
allowing its comparison with our previously reported homology
model [15] that was used in the virtual screening protocol.
Figure 4A shows a superimposition of our initial homology model
and the crystal structure of transketolase highlighting a high
similarity with a backbone RMSd of only 1.1 A ˚ (for modeled
monomer 1 and 331 atom pairs) and 1.2 A ˚ (for modeled monomer
2 and 330 atom pairs). Overall our model predicted correctly the
main structural parts of the protein, although the uncommon long
loop of transketolase found in K282-A320 was not well predicted
(Figure 4A between arrows). Nonetheless, this sequence is solvent
exposed not participating in dimer stabilization nor catalytical
activity. It is worth mentioning that the proposed pharmacophore
used in this study (formed by Q203, K204 and E207) can be also
extracted, with minor distances differences (all atom RMSd of
1.77 A ˚ and 1.82 A ˚ for modeled monomer 1 and 2, respectively),
from the crystal structure of human transketolase (Figure 4B).
Thereby, either our model or the crystal structure should be
Figure 2. Structures of the reported diphenyl urea derivatives. In the upper part, compounds which showed good inhibitory activity. In the
bottom part, compounds which showed poor activity. The pharmacophoric points are also shown; in red for hydrogen acceptor points, in blue for
hydrogen donor points and in green for hydrophobic points.
doi:10.1371/journal.pone.0032276.g002
Table 1. Activities of the reported diphenyl urea derivatives.
IC50 (mM) Transketolase from cell extract Cell viability (HT29/HCT116 cells)
T2 200 10/9
T2A 150 15/17
T2B 100 6/12
T2C ..200 200/200
T2D ..200 .200/.200
T2E ..200 20/13
T2F ..200 na
doi:10.1371/journal.pone.0032276.t001
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used in our virtual screening protocol.
Conclusions
Novel phenyl urea derivatives have been described as inhibitors
of human transketolase, an excellent target for the advent of new
anticancer drugs. Notably, the proposed binding mode of
compounds involves interactions with the alpha helix sequence
D200-G210 interfering likely with the enzyme dimerization.
Although the activity of the reported inhibitors is only in the
micromolar range, their proposed novel binding site and binding
mode can be used for the rational design of future more potent
inhibitors of transketolase not based on mimicking the non drug-
like thiamine pyrophosphate cofactor.
Materials and Methods
Virtual screening protocol
The homology model of human transketolase previously
reported [15] was used to scan for the hot spots responsible for
dimer stabilization. The model was energy-minimized and
subjected to a molecular dynamics simulation (MD) using the
Amber program [17] and the ff94 and GAFF force fields [18]. MD
temperature was set to 300 K in increments of 30 K/10 ps and
optimal density was reached by a NPT step of 40 ps. Then, the
system was simulated in the NVT ensemble for 7 ns. Stabilization
of total energy was obtained in the last 1.6 ns, that were
considered, therefore, the production time and were used for the
further analysis of interactions. Hydrogen bonds, van der Waals
contacts and electrostatic interactions formed between the two
transketolase monomers were monitored throughout the produc-
tion time of the molecular dynamics simulation [15] extracting the
van der Waals and electrostatics components of the force field. For
this purpose, the energies of each residue of one monomer of
transketolase against the complete other monomer were obtained
(no cut-off was used). Those residues with higher values were
visually inspected in order to deduce a protein-protein pharma-
cophore. In this stage not only the interaction energies were
considered but also the type of interactions and the sequence
conservation with respect to the template.
Subsequently, the pharmacophore was introduced as a
hypothesis for database screening employing the Catalyst program
(Accelrys Inc. CATALYST
TM) and the following libraries of
commercially available compounds: Mini Maybridge, SPECS, Nat
Diverse, ACD, IBS, NCI, Aurora and Derwent. Search concluded
with 128 drug-like hits that accomplished the pharmacophore
Figure 3. Proposed binding mode of compound T2 and its derivatives (T2A–T2F). Black dots represent hydrogen bonds.
doi:10.1371/journal.pone.0032276.g003
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acquired and refined trough a docking-scoring protocol. Docking
was performed with our home-made program Dock_Dyn [19] by
imposing the pharmacophore constraint to all conformations. This
process selects only those conformations that fulfill the pharma-
cophore restriction speeding up the docking process. First ranking
of ligands was obtained by evaluating their pharmacophore RMSd
compared with the protein pharmacophore. In order to account
slightly for the protein flexibility, the atom radii of both the
receptor and the ligands were reduced by 40%, allowing therefore
a minor steric clash in the binding site. After that, the empirical-
based scoring function XSCORE [16] was utilized to score and
rank all docking solutions. Best ranked compounds according to
RMSd and XSCORE criteria were visually inspected both in
Table 2. Ligand-receptor interactions, contribution of the nitro group and MMPBSA energy for all compounds.
Compound Ligand-receptor interactions
Electrostatic intermolecular energy
of the nitro group (kcal/mol)
1 MMPBSA energy (kcal/mol)
2
T2 Urea amino groups-E207 (HB)
Hydroxyl-E207 (HB)
Nitro-K204 (HB)
m-chlorophenyl-Q203 (VDW)
220 225.03
T2A Urea amino groups-E207 (HB)
Nitro-K204 (HB)
Hydroxynaphtalene-Q203 (HB)
Hydroxynaphtalene-Q203 (VDW)
222 215.21
T2B Urea amino groups-E207 (HB)
Hydroxyl-E207 (HB)
Nitro-K204 (HB)
Phenyl-Q203 (VDW)
225 215.66
T2C Urea amino groups-E207 (HB)
Carboxylate-K204 (HB)
o-methyl,m-chlorophenyl-Q203 (VDW)
210 (carboxylate) 214.67
T2D Urea amino groups-E207 (HB)
Nitro-K204 (HB)
o,p-diethylphenyl-Q203 (VDW)
225 212.16
T2E Urea amino groups-E207 (HB)
Hydroxyl-E207 (HB)
Nitro-K204 (HB)
o-hydroxy,m-chlorophenyl-Q203 (VDW)
225 219.05
T2F Urea amino groups-E207 (HB)
carbonyl-K204 (HB)
o-methyl, m-chlorophenyl-Q203 (VDW)
none 214.53
HB denotes for hydrogen bond formation, VDW denotes for van der Waals interaction.
1: Extracted from the electrostatic term of the force field.
2: MMPBSA energy without computing the entropy contribution to binding.
doi:10.1371/journal.pone.0032276.t002
Figure 4. Comparison of transketolase model with crystal structure. A) Superimposition of the homology model of human transketolase (in
pink) with the recently released crystal structure (in white). B) Close view of the residues used for pharmacophore definition, in the homology model
(in pink and thin residues) and in the crystal structure (in white and thick residues).
doi:10.1371/journal.pone.0032276.g004
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tions, and purchased for experimental validation. Moreover the
intermolecular force field contributions of the nitro groups (or the
equivalent carboxylate group) of the compounds were analyzed to
qualitatively measure the differences in binding affinity. Addition-
ally an MMPBSA protocol [20] was performed by taking the
minimized docked structures. Entropy calculation was neglected
assuming that it will remain constant among the derivatives due to
their similarity.
Purchase of compounds
Seven compounds were acquired from commercial suppliers in
their highest purity (.80%): compound T2 (Sigma Aldrich;
id=S715719-1EA), compound T2A (Salor Sigma; id=S847984),
compound T2B (LaboTest Stock; id=LT03054002), compound
T2C (Scientific Exchange Products; id=M-640547), compound
T2D (Scientific Exchange Products; id=M-442855), compound
T2E (Scientific Exchange Products; id=M-620773) and com-
pound T2F (Sigma Aldrich; id=S867616). Positive ESI Mass
Spectra results for all the studied compounds are included in the
Supplementary material (Tables S3, S4, S5, S6, S7, S8, S9, S10).
Cell culture
HCT116 human colon carcinoma cells (gift from Dr Capella `,
Institut Catala ` d’Oncologia, Barcelona, Spain) were grown in
DMEM:HAM F12 (1:1), supplemented with 10% heat-inactivated
foetal calf serum (FCS) (PAA Laboratories, Pasching, Austria), L-
glutamine (2 mM), pyruvic acid (1 mM), non-essential aminoacids
(1%) and antibiotics: 100 U6mL
21 penicillin and 100 mg6mL
21
streptomycin. HT29 human colon adenocarcinoma cells (obtained
from the American Type Culture Collection -ATCC-) were grown
in Dulbecco’s Modified Eagle’s Medium, 25 mM D-glucose,
4m M L-glutamine supplemented with 10% heat-inactivated
FCS, and antibiotics: 100 U6mL
21 penicillin and 100 mg6mL
21
streptomycin (Invitrogen, Paisley, UK). All cell cultures were
carried out at 37uC in a humidified atmosphere with 5% CO2.
Subconfluent monolayers of cells were used in all experiments.
Preparation of cell extracts for enzyme activity studies
Cell cultures were washed with PBS, detached from the flasks
using 0.025% trypsin-EDTA and then resuspended in lysis buffer
(1 mM dithiothreitol, 1 mM EDTA, 0.02% Triton X-100, 0.02%
sodium deoxycholate, 0.2 mM phenylmethylsulfonyl fluoride, 1%
sodium azide and 20 mM Tris-HCl, pH 7.5). Cells were
homogenized using a laboratory sonicator (1/2 Liter Branson
200 Ultrasonic bath, 5 min, 40 kHz, 4uC) and immediately
ultracentrifuged at 1050006g for 1 hour at 4uC. The supernatant
was separated and approximately 300 mg of protein cell extract
used for the determination of transketolase enzyme activity using a
Cobas Mira Plus chemistry analyzer (HORIBA ABX, Montpel-
lier, France) or a spectrofluorimeter Kontron SFM-25 (Bio-Tek
Instruments, VT, United States).
Determination of transketolase activity
Transketolase (EC 2.2.1.1) activity was determined using the
enzyme linked method described by Smeets and colleagues [21].
Briefly, cell extract and inhibitors were added to a cuvette
containing 5 mM MgCl2, 0.2 U6mL
21 glycerophsphate dehy-
drogenase-triosephosphate isomerase (from rabbit muscle),
0.2 mM NADH, 0.1 mM thiamine pyrophosphate (TPP) and
50 mM Tris-HCl, pH 7.6 at 37uC. The reaction was initiated by
the addition of 300 mL substrate mixture (see below) per mL of
cuvette volume. The oxidation of NADH, which is directly
proportional to transketolase activity, was followed by the decrease
in absorbance at 340 nm (spectrophotometric method) or in
fluorescence at 450 nm when excited at 330 nm (fluorimetric
method) before and after the addition of the different compounds
tested. A blank with all the assay components but the sample was
performed in each experiment by measuring the oxidation of
NADH. The substrate mixture was prepared by dissolving 50 mM
ribose-5-phosphate in 50 mM Tris-HCl, pH 7.6, and adding
0.05 IU ribulose-5-phosphate-3-epimerase (from baker’s yeast)
and 0.25 IU phosphoriboisomerase (from spinach). The substrate
mixture was continuously stirred and heated for 1 hour at 37uC
and then kept at 220uC until use.
Protein concentration of cell extracts was determined using the
BCA Protein Assay (Pierce Biotechnology, Rockford, IL) to
calculate the specific activity of the transketolase enzyme.
MTT assay
CellviabilitywasdeterminedusingtheMTTassay,whichisbased
on the ability of live cells to cleave the tetrazolium ring, thus
producing formazan, which absorbs at 570 nm. 5000 cells/well
HT29 cells or 1700 cells/well HCT116 cells were seeded into 96-
well plates and incubated for 24 h prior to the addition of the
different compounds at different concentrations, in triplicate. After
incubation for 72 h, the supernatant was aspirated and 100 mLo f
filtered MTT (0.5 mg/mL) was added to each well. Following 1 h of
incubation, the supernatant was removed and the formazan
precipitated was dissolved in DMSO. Relative cell viability was
measured by absorbance at 550 nm on an ELISA plate reader
(Tecan Sunrise MR20-301, TECAN, Austria). Concentrations that
inhibitedcellgrowthby50%(IC50)aftertreatmentweredetermined.
Supporting Information
Figure S1 Transketolase activity in cell extracts after T2 and T4
incubation using spectrophotometric and fluorimetric methods.
(PDF)
Figure S2 Transketolase activity in cell extracts after T2A and
T2B incubation (upper panels). Dose response curves of cell
viability after 72 h T2B incubation in HT29 and HCT116 cells
(lower panels).
(PDF)
Table S1 Smiles and MDL numbers of best ranked molecules.
(XLS)
Table S2 XSCORE and pharmacophore RMSd of T2 and T2
derivatives.
(XLS)
Table S3 Positive ESI Mass Spectra results for T2 compound.
(PDF)
Table S4 Positive ESI Mass Spectra results for T2A compound.
(PDF)
Table S5 Positive ESI Mass Spectra results for T2B compound.
(PDF)
Table S6 Positive ESI Mass Spectra results for T2C compound.
(PDF)
Table S7 Positive ESI Mass Spectra results for T2D compound.
(PDF)
Table S8 Positive ESI Mass Spectra results for T2E compound.
(PDF)
Table S9 Positive ESI Mass Spectra results for T2F compound.
(PDF)
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